Open access · CC-BY
via OpenAlex
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
Jiří Patočka, Kamil Kuča, Patrik Olekšák, Eugenie Nepovimová, Martin Vališ, Michal Novotný, Blanka Klímová
Pharmaceuticals · 2021 · ▲ 44 citations
Abstract
Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) could be one of them. The authors performed a systematic literature review of available studies on the research describing rapamycin in association with COVID-19 infection. Only peer-reviewed English-written articles from the world's acknowledged databases Web of Science, PubMed, Springer and Scopus were involved. Five articles were eventually included in the final analysis. The findings indicate that rapamycin seems to be a suitable candidate for drug repurposing. In addition, it may represent a better candidate for COVID-19 therapy than commonly tested antivirals. It is also likely that its efficiency will not be reduced by the high rate of viral RNA mutation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ph14030217
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Patočka, J., Kuča, K., Olekšák, P., Nepovimová, E., Vališ, M., Novotný, M., & Klímová, B. (2021). Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph14030217
Vancouver
Patočka J, Kuča K, Olekšák P, Nepovimová E, Vališ M, Novotný M, et al. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. Pharmaceuticals. 2021. doi:10.3390/ph14030217.
BibTeX
@article{ji2021Rapamy,
title = {Rapamycin: Drug Repurposing in SARS-CoV-2 Infection},
author = {Jiří Patočka and Kamil Kuča and Patrik Olekšák and Eugenie Nepovimová and Martin Vališ and Michal Novotný and Blanka Klímová},
journal = {Pharmaceuticals},
year = {2021},
doi = {10.3390/ph14030217},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Molecular Sciences 2021
Open access · CC-BY
Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process
Journal of Personalized Medicine 2023
Open access · CC-BY
mTOR Inhibition via Low-Dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve?
Nature Metabolism 2022
Open access · OA
Viral infection as an NAD+ battlefield
Preprints.org 2023
Preprint · CC-BY
mTOR Inhibition via Low-dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve
FASEB bioAdvances 2026
Open access · OA
Retrotransposons in Bone and Joint Diseases.
TURKISH JOURNAL OF BIOLOGY 2020
Open access · CC-BY